Paper41595154
Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk.
Bruinsma RS and 12 others. Cancers (Basel), 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk. Papers, record 41595154. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41595154
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21862876 | Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. | Cell Cycle | 2011 | https://conductscience.org/library/papers/21862876 | PubMed |
| 2 | 20516441 | Accumulation of segmental alterations determines progression in neuroblastoma. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20516441 | PubMed |
| 3 | 19047291 | The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19047291 | PubMed |
| 4 | 35100718 | Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. | JCO Precis Oncol | 2019 | https://conductscience.org/library/papers/35100718 | PubMed |
| 5 | 36162542 | Tumoral heterogeneity in neuroblastoma. | Biochim Biophys Acta Rev Cancer | 2022 | https://conductscience.org/library/papers/36162542 | PubMed |
| 6 | 8889347 | A note on quantifying follow-up in studies of failure time. | Control Clin Trials | 1996 | https://conductscience.org/library/papers/8889347 | PubMed |
| 7 | 35859155 | Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. | Sci Rep | 2022 | https://conductscience.org/library/papers/35859155 | PubMed |
| 8 | 28561228 | 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. | Klin Padiatr | 2017 | https://conductscience.org/library/papers/28561228 | PubMed |
| 9 | 25741868 | Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. | Genet Med | 2015 | https://conductscience.org/library/papers/25741868 | PubMed |
| 10 | 34115544 | Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34115544 | PubMed |
| 11 | 39893454 | How much missing data is too much to impute for longitudinal health indicators? A preliminary guideline for the choice of the extent of missing proportion to impute with multiple imputation by chained equations. | Popul Health Metr | 2025 | https://conductscience.org/library/papers/39893454 | PubMed |
| 12 | 25517749 | ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. | Cancer Cell | 2014 | https://conductscience.org/library/papers/25517749 | PubMed |
| 13 | 21632861 | High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21632861 | PubMed |
| 14 | 39796644 | Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39796644 | PubMed |
| 15 | 34319759 | Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34319759 | PubMed |
| 16 | 37169874 | Clonal evolution during metastatic spread in high-risk neuroblastoma. | Nat Genet | 2023 | https://conductscience.org/library/papers/37169874 | PubMed |
| 17 | 24045179 | Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/24045179 | PubMed |
| 18 | 34636058 | Neuroblastoma-Telomere maintenance, deregulated signaling transduction and beyond. | Int J Cancer | 2022 | https://conductscience.org/library/papers/34636058 | PubMed |
| 19 | 36807339 | Genomic ALK alterations in primary and relapsed neuroblastoma. | Br J Cancer | 2023 | https://conductscience.org/library/papers/36807339 | PubMed |
| 20 | 30754710 | The Evolution of Risk Classification for Neuroblastoma. | Children (Basel) | 2019 | https://conductscience.org/library/papers/30754710 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CDK4 | 1019 | PubTator's text mining | https://conductscience.org/library/genes/1019 | NCBI Gene |
| MDM2 | 4193 | PubTator's text mining | https://conductscience.org/library/genes/4193 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41595154
GET https://conductscience.org/api/papers/v1/41595154/references?page=2